Billiontoone’s (BLLN) Buy Rating Reiterated at BTIG Research

Billiontoone (NASDAQ:BLLN)‘s stock had its “buy” rating restated by stock analysts at BTIG Research in a report released on Thursday, Marketbeat Ratings reports. They presently have a $130.00 price objective on the stock. BTIG Research‘s price target would indicate a potential upside of 14.15% from the stock’s current price.

Several other brokerages have also recently issued reports on BLLN. Canaccord Genuity Group began coverage on Billiontoone in a report on Wednesday, September 2nd. They set a “buy” rating and a $120.00 price objective on the stock. Weiss Ratings lowered shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, October 8th. JPMorgan Chase & Co. dropped their price objective on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating for the company in a research note on Thursday, August 6th. Zacks Research upgraded shares of Billiontoone from a “strong sell” rating to a “hold” rating in a research report on Friday, October 2nd. Finally, Guggenheim boosted their target price on Billiontoone from $125.00 to $128.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $126.25.

Billiontoone Trading Up 3.1%

Billiontoone stock opened at $113.89 on Thursday. The business has a 50-day simple moving average of $104.67 and a two-hundred day simple moving average of $96.89. The company has a market cap of $5.37 billion and a P/E ratio of 162.70. Billiontoone has a 52-week low of $61.96 and a 52-week high of $150.44. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17.

Billiontoone (NASDAQ:BLLN) last issued its earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, hitting the consensus estimate of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The company had revenue of $109.45 million during the quarter. Analysts predict that Billiontoone will post 0.80 EPS for the current year.

Insider Transactions at Billiontoone

In other news, CEO Oguzhan Atay sold 25,001 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $109.24, for a total transaction of $2,731,109.24. Following the transaction, the chief executive officer owned 16,667 shares in the company, valued at $1,820,703.08. This represents a 60.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Bosch John Roderick Ten sold 2,834 shares of Billiontoone stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $113.17, for a total value of $320,723.78. Following the sale, the senior vice president directly owned 16,551 shares of the company’s stock, valued at $1,873,076.67. This trade represents a 14.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 264,194 shares of company stock valued at $27,797,333 in the last quarter. 50.22% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Billiontoone

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Penn Capital Management Company LLC lifted its position in Billiontoone by 2.3% in the third quarter. Penn Capital Management Company LLC now owns 132,636 shares of the company’s stock valued at $14,143,000 after buying an additional 3,034 shares during the last quarter. Parallel Advisors LLC increased its position in shares of Billiontoone by 86.7% during the third quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $30,000 after acquiring an additional 130 shares during the last quarter. Provenance Wealth Advisors LLC acquired a new stake in shares of Billiontoone during the third quarter valued at about $56,000. D.A. Davidson & CO. purchased a new stake in shares of Billiontoone in the 3rd quarter valued at approximately $773,000. Finally, Forum Financial Management LP purchased a new position in shares of Billiontoone during the 3rd quarter worth approximately $274,000.

Key Stories Impacting Billiontoone

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q3 results beat estimates: Revenue was approximately $123 million, above the $115.8 million FactSet estimate. Reports put quarterly EPS at either $0.32 or $0.48, both above the $0.16 consensus; the reports differ on the EPS figure. Q3 earnings report
• Positive Sentiment: Raised outlook and upcoming launch: BillionToOne lifted its 2026 revenue guidance to $460 million–$470 million and said it plans to launch Northstar Clear on December 15. Higher guidance and a new product launch may support expectations for growth. Guidance and Northstar Clear announcement
• Negative Sentiment: Executives reported stock sales: CEO Oguzhan Atay, CTO David Tsao and SVP Bosch John Roderick Ten sold shares on November 2. The sales were conducted under pre-arranged Rule 10b5-1 plans, which may reduce—but do not eliminate—the concern investors could attach to insider selling. Insider transaction report

Billiontoone Company Profile

BillionToOne, Inc is a molecular diagnostics company that develops tests designed to provide more sensitive and quantitative genetic information from blood samples. The company’s technology is based on its proprietary Quantitative Counting Template (QCT) platform, which is designed to measure DNA molecules with high sensitivity and support the detection of clinically meaningful genetic signals.

The company’s products include prenatal diagnostic and screening solutions marketed under the UNITY brand.